# The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

> **NCT03236649** · PHASE3 · TERMINATED · sponsor: **Beijing Shenogen Biomedical Co., Ltd** · enrollment: 89 (actual)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Icaritin
- **DRUG:** Sorafenib Tosylate Tablets

## Key facts

- **NCT ID:** NCT03236649
- **Lead sponsor:** Beijing Shenogen Biomedical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-20
- **Primary completion:** 2022-02-08
- **Final completion:** 2022-02-08
- **Target enrollment:** 89 (ACTUAL)
- **Why stopped:** Because the clinical development plan has been changed.
- **Last updated:** 2023-02-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03236649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03236649, "The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03236649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*